Villepinte (France), February 19, 2018 (08:00 CET) - Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, has announced the appointment of David Hale as Chief Commercial Officer Diagnostic Imaging.

"We are delighted to welcome David as a new member of our Executive Committee. His solid international experience, leadership and knowledge of the commercial challenges facing the radiology industry, in particular in the fields of digital solutions, technical services and equipment, will be invaluable assets as we continue our growth in diagnostic imaging by developing a comprehensive range addressing radiologists' needs," said Yves L'Epine, Chief Executive Officer, Guerbet.

David is joining Guerbet after 17 years spent with General Electric Healthcare where he was President of Enterprise Imaging and Care Area Software Solutions, having also held various sales, marketing and development positions both regionally and globally.

David Hale has dual American and French nationality and holds a degree in Industrial and Systems Engineering from the Georgia Institute of Technology (USA) and an MBA from the International Institute for Management Development business school (Lausanne, Switzerland).

Diagnostic imaging is Guerbet's core business, an activity that covers all of the products, services and solutions used in this specialty field, from CT/cath lab and MRI contrast media to injectors, injection medical devices, software and service activities. Guerbet has already built a strong position for itself in this segment with leading brands.


Guerbet is a pioneer in the contrast agent field, with more than 90 years' experience, and is a leader in medical imaging worldwide. It offers a comprehensive range of pharmaceutical products, medical devices and services for diagnostic and interventional imaging, to improve treatment of patients. With 7% of revenue dedicated to R&D and more than 200 R&D employees distributed amongst its three centers in France and the United States, Guerbet is a substantial investor in research and innovation. Guerbet (GBT) is listed on Euronext Paris (segment B - mid caps) and generated €807 million in revenue in 2017. For more information about Guerbet, visit www.guerbet.com

More People on the Move